AAM to Present at the Wolfe Research Virtual Autos Summit on March 18
AAM is scheduled to participate in a fireside chat at 11:40 a.m. ET. The live webcast will be accessible through the Investor Relations page on AAM's website (www.aam.com). A replay of the webcast will be available following the event.
About AAMAs a leading global Tier 1 Automotive and Mobility Supplier, AAM designs, engineers and manufactures Driveline and Metal Forming technologies to support electric, hybrid and internal combustion vehicles. Headquartered in Detroit, MI, with over 75 facilities in 16 countries, AAM is bringing the future faster for a safer and more sustainable tomorrow. To learn more, visit aam.com.
Our presentation may contain "forward-looking" statements that are subject to risks and uncertainties described in our most recent filings on Form 10-K and Form 10-Q with the Securities and Exchange Commission, and actual results may differ materially. Our presentation may also include certain non-GAAP financial measures. Information regarding these non-GAAP measures, as well as a reconciliation of these non-GAAP measures to GAAP financial information, is available on AAM's website.
For more information:
Investor Contact:David H. LimHead of Investor Relations(313) 758-2006david.lim@aam.com
Media Contact:Christopher M. Son Vice President, Marketing & Communications (313) 758-4814 chris.son@aam.com
Or visit the AAM website at www.aam.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/aam-to-present-at-the-wolfe-research-virtual-autos-summit-on-march-18-302395947.html
SOURCE American Axle & Manufacturing Holdings, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
11 minutes ago
- Business Wire
Power and Portability Meet Toughness. New Use Energy Unveils the Revolutionary 605 SunCase™: Ultra-Portable Power at Just 16 lbs.
ANACORTES, Wash.--(BUSINESS WIRE)--In direct response to requests from various Special Forces, Military Medical, Drone, and Counter Drone units, New Use Energy Solutions, Inc. (NUE), a leading innovator in ruggedized mobile solar-plus-battery generator systems, today announced the highly anticipated launch of its 605 SunCase™. At an astonishingly light 16 pounds, the 605 SunCase™ is a groundbreaking portable power solution. It's designed for unparalleled mobility and silent operation, delivering robust, reliable power in the toughest conditions. The 605 SunCase™ redefines what's possible in portable power, packing a powerful 550Wh LiFePO4 battery and a 600W pure sine wave inverter into a compact, weather-resistant, fire-retardant, thermoplastic case. Its featherlight design and grab-and-go portability make it an indispensable tool where traditional, heavy, and noisy generators are impractical or prohibited and consumer grade units just don't take the beating. "The 605 SunCase™ is a testament to our commitment to innovation and understanding the critical needs of our users," said Paul Shmotolohka, CEO of New Use Energy. "We've engineered a solution that delivers power without the weight, noise, or heat signature of conventional generators. This unit empowers professionals across diverse fields—from military personnel to cinematographers in remote location to operate with unprecedented freedom and efficiency, ultimately enhancing their capabilities and ensuring mission success." Key Features and Impact of the 605 SunCase™: Ultra-Portable at 16 lbs (7 kg): Its light weight allows for easy transport and deployment in challenging terrains, tight spaces, or rapid-response scenarios, expanding operational possibilities. Silent, Fuel-Free Operation: Unlike gas generators, the 605 SunCase™ operates silently with no emissions or heat signature, making it ideal for stealth operations in electronic warfare, quiet film sets, or indoor use. Rugged & Reliable: Encased in a tough, weather-resistant shell (conforming to IP55), it's built to withstand major shocks, drops, and extreme temperatures, drawing on NUE's proven durability in demanding environments, including war zones. Empowering the Creative: For film and TV production, the 605 SunCase™ liberates lighting and camera crews from the constraints of "bandit cable" and centralized generators for basic equipment charging such as cameras and monitors. Critical Military & Emergency Support: Building on NUE's success in powering over 40 brigades in the US and Ukraine, the 605 SunCase™ is perfectly suited for powering sensitive equipment for drone teams (signal boosters, goggles, monitors), dismounted battlefield intelligence, and critical medical devices (IV pumps, ventilators) where uninterrupted power is non-negotiable. Its rapid 20-millisecond transfer time ensures seamless operation during power fluctuations. Versatile Charging: The 605 SunCase™ features multiple output options (AC, USB-A, USB-C, 12V DC) and can be rapidly recharged via solar (built-in 400W MPPT controller), AC, or vehicle alternators. The launch of the 605 SunCase™ reinforces New Use Energy's commitment to providing cutting-edge, environmentally conscious power solutions that enhance user experience and operational outcomes. It's not just a power station; it's a force multiplier for those who demand the best in portable energy. The new 605 SunCase™ is available for purchase starting September 2025 through New Use Energy's website and authorized dealers. About New Use Energy New Use Energy Solutions, Inc. is an American company leading the development and distribution of proprietary, state-of-the-art, ruggedized mobile solar-plus-battery generator systems. Engineered for the most demanding commercial, industrial, and government applications, NUE delivers clean, renewable, and reliable power wherever it is needed. With a proven track record in military, emergency response, and humanitarian aid, NUE is committed to creating a new generation of energy sources that respond to the challenges of modern times, empowering professionals, communities, and the planet.
Yahoo
an hour ago
- Yahoo
3 Dow Jones Dividend Stocks With Above-Average Yields You Can Buy Now and Hold for at Least a Decade
Key Points UnitedHealth Group's reduced profit forecast for 2025 is disappointing, but the health insurance business is in a good position to bounce back. Coca-Cola's dividend payout has risen for 63 consecutive years. Amgen sells over a dozen drugs that are growing sales at a double-digit annual percentage. 10 stocks we like better than UnitedHealth Group › Income-seeking investors who value their time know the best dividend stocks don't need a lot of babysitting. Some go on decades-long payout-raising streaks. The Dow Jones Industrial Average (DJINDICES: ^DJI) is one of the best places to find reliable dividend payers. Stocks aren't added to this exclusive list unless they have already demonstrated an ability to produce profits in good economic times and bad ones, too. The average dividend payer in the Dow Jones Industrial Average offers a measly 1.6% yield at recent prices. UnitedHealth Group (NYSE: UNH), Coca-Cola (NYSE: KO), and Amgen (NASDAQ: AMGN) stand out with above-average yields. Here's why they could be great additions to a long-term dividend investor's portfolio. 1. UnitedHealth Group Shares of UnitedHealth Group collapsed in May, after the company simultaneously suspended its 2025 outlook and announced an abrupt CEO exit. To top it off, the company felt it was necessary to issue responses to several Wall Street Journal articles and a Department of Justice investigation regarding its Medicare business. The stock is down, but its dividend payout is way up. The company raised it by 76.8% over the past five years. At its beaten-down price, the stock offers a 2.7% yield. Health insurance businesses operate on thin margins. It turns out that UnitedHealth mispriced premiums going into 2025. Healthcare providers are charging more than the company anticipated, plus the amount of care new members have been using is also higher than expected. Smart investors such as Warren Buffett know that UnitedHealth Group is mostly a middleman that can pass increased costs on to health plan sponsors. It may have mispriced premiums going into 2025, but this isn't a mistake its recently refreshed management team is likely to make again in the decade ahead. 2. Coca-Cola Unlike UnitedHealth, Coca-Cola stock is up near its all-time high. The soda giant's dividend hasn't risen as sharply as the health insurer's, but it's still up by 24.4% over the past five years. Being the only company that can sell many of the world's most popular beverage brands is a strong advantage that leads to consistent profits. In February, the company announced a dividend raise for the 63rd year in a row. Shares of Coca-Cola offer a 2.9% yield at recent prices, and another decade of significant dividend raises isn't an unreasonable expectation. Second-quarter unit case volume fell by 1%, but the strength of its brands allowed organic revenue to rise by 5% year over year. Sales of sugary sodas have been losing ground to sports drinks, but the company has this base covered. Its BodyArmor brand boasts a double-digit share of the U.S. market, and its older Powerade brand is even more popular. Adding some shares of this stock to a diverse portfolio is an almost certain way to boost your passive income stream over time. 3. Amgen Shares of biotechnology pioneer Amgen have been trading about 12% below the all-time high they set last year. Amgen began paying a dividend in 2011 and has been able to increase it every year since. The drugmaker raised its payout by 48.8% over the past five years. At recent prices, it offers a 3.2% yield. Two of Amgen's top revenue streams, Enbrel and Prolia, are drying up thanks to biosimilar competition. Fortunately, the losses are easily offset by a slew of more recently launched products. Amgen recently reported year-over-year sales increases at a double-digit percentage for 15 products in the second quarter. New competition for Enbrel and Prolia limited second-quarter sales growth to 9% year over year. Enbrel and Prolia losses will most likely reach a bottom long before Amgen's new growth drivers run out of fuel. With a strong lineup of new products, this company could report strong sales growth in the decade ahead. Should you buy stock in UnitedHealth Group right now? Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy. 3 Dow Jones Dividend Stocks With Above-Average Yields You Can Buy Now and Hold for at Least a Decade was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
Combination Cancer Therapies Surge: The Young Adult Treatment Revolution
As cancer rates climb 30% among adults under 50, combination immunotherapy companies are advancing breakthrough treatments and institutional investors are committing $243.62 billion to capture the rapidly expanding precision oncology market. A medical crisis is reshaping the cancer treatment landscape. Young adults under 50 are experiencing unprecedented cancer rates, with aggressive tumors requiring innovative combination approaches that go far beyond traditional single-drug therapies. According to Memorial Sloan Kettering Cancer Center, cancer incidence rates in women under 50 are now 82% higher than their male counterparts, up from 51% in 2002. The American Cancer Society reports that colorectal cancer has become the leading cause of cancer deaths among young men and the second leading cause among young women, fundamentally changing treatment priorities across the oncology spectrum. The market response reflects this urgency. Mordor Intelligence projects the global cancer therapy market will surge from $243.62 billion in 2025 to $403.99 billion by 2030, reflecting a 10.64% CAGR driven by demand for combination therapies specifically designed to combat the more aggressive cancers plaguing younger demographics. Keep reading to discover how combination immunotherapy approaches are revolutionizing treatment for young adult cancer patients and which companies are positioned to dominate this rapidly evolving market. For a detailed analysis of one company leading this transformation, click here. Leading Companies in the Combination Therapy Revolution Combination immunotherapy is attracting significant institutional investment, with these companies making strategic moves: AstraZeneca PLC (NASDAQ: AZN) --- AstraZeneca recently received FDA Priority Review and Breakthrough Therapy Designation for its Imfinzi immunotherapy in early-stage gastric cancers, with FDA decision anticipated in Q4 2025. The perioperative combination regimen showed a 29% reduction in disease progression risk, positioning the company to capture significant market share as gastric cancers increasingly affect younger populations with more aggressive disease patterns. Bristol Myers Squibb Company (NYSE: BMY) --- Bristol Myers Squibb recently secured FDA approval for its Opdivo-Yervoy combination as first-line treatment for unresectable liver cancer, converting a previous accelerated approval. The dual checkpoint inhibitor regimen directly competes with rival immunotherapy combinations and offers potential for longer survival compared to traditional targeted therapies, particularly relevant as liver cancers show rising incidence in younger adults. Amgen Inc. (NASDAQ: AMGN) --- Amgen recently gained FDA approval for Imdelltra, its breakthrough bispecific T-cell engager for extensive-stage small-cell lung cancer, with pricing at $31,500 per first cycle. The drug demonstrated a tripling of survival duration to 14.3 months median overall survival in a disease where median survival typically reaches only 5 months, addressing the urgent need for effective treatments in the deadliest form of lung cancer. Pfizer Inc. (NYSE: PFE) --- Pfizer recently showcased breakthrough data across its oncology portfolio at ASCO 2025, featuring combination approaches in breast, genitourinary, and thoracic cancers. The company's Braftovi combination doubled survival time for patients with aggressive colorectal cancer in late-stage trials, representing significant progress for a cancer type that disproportionately affects younger adults with traditionally poor prognosis and limited treatment options. The $403.99 Billion Combination Therapy Opportunity The convergence of rising young adult cancer rates and breakthrough combination immunotherapies is creating unprecedented market expansion across every segment of oncology treatment. Read: Mining Stocks Finally Wake Up as Gold Stays Hot Above $3,300 $40 Silver Breakout Imminent as Miners Enter High-Momentum Phase Encryption Is Dying—Here's What Comes Next for Cyber Defense FDA Fast-Track Cancer Treatments Drive $900B Market Growth Forecast Mining Stocks Outpace Gold's Historic Rally as Sector Primes for Breakout According to Mordor Intelligence, the global cancer therapy market will reach $403.99 billion by 2030, with combination immunotherapies representing the fastest-growing segment. The shift toward treating younger patients with more aggressive cancers requiring multi-drug approaches is fundamentally altering treatment economics and creating new revenue opportunities for companies developing sophisticated combination regimens. Precedence Research forecasts the cancer therapeutics market will expand from $194.67 billion in 2024 to $469.38 billion by 2034, representing a 9.20% CAGR. This explosive growth is being driven by the unique challenges of treating younger patients whose cancers often resist single-agent therapies and require novel combinations of checkpoint inhibitors, targeted therapies, and next-generation immunomodulators specifically designed for aggressive tumor biology. Global Market Insights projects the oncology market will reach $866.1 billion by 2034, growing at a 10.8% CAGR. The market expansion is being accelerated by the urgent need to address the 30% surge in young adult cancer cases projected through 2030, with combination therapies representing the most promising approach to combat the treatment-resistant, aggressive cancers increasingly diagnosed in this demographic. The Bottom Line The combination therapy revolution is accelerating rapidly, driven by the unprecedented cancer epidemic affecting young adults who require more sophisticated treatment approaches than traditional single-drug regimens can provide. With aggressive cancers becoming more prevalent in younger demographics, the demand for innovative combination immunotherapies is creating massive market opportunities. Institutional investors are positioning for explosive growth as companies develop next-generation combination platforms specifically designed to address the unique molecular characteristics and treatment resistance patterns exhibited by cancers in younger patients. While the companies mentioned represent established leaders in combination therapy development, one innovative biotech has quietly advanced a viral immunotherapy platform that combines multiple mechanisms of action in a single treatment approach. To learn more about this emerging opportunity, click here.
